(Total Views: 624)
Posted On: 02/15/2023 9:17:57 AM
Post# of 154788
Cyrus has mentioned attacking colorectal cancer based on favorable leronlimab data.
A cancer space competitor stopped their Phase 3 colorectal Ca trial, since the drug arm wasn't doing well compared to placebo. I own no shares in GTHX, which markets its drug as Cosela, already approved for late stage Lung Ca treatment. (Share price dropped 50% on 2/13/23 with the trial stop news.)
Me?? Yes, I want to use my bull-in-a-china(*dishware)-shop style to crash into the NASH and cancer markets. I'm aware that a different style is necessary for the FDA, et al, but it's nice of you to ask.
A cancer space competitor stopped their Phase 3 colorectal Ca trial, since the drug arm wasn't doing well compared to placebo. I own no shares in GTHX, which markets its drug as Cosela, already approved for late stage Lung Ca treatment. (Share price dropped 50% on 2/13/23 with the trial stop news.)
Me?? Yes, I want to use my bull-in-a-china(*dishware)-shop style to crash into the NASH and cancer markets. I'm aware that a different style is necessary for the FDA, et al, but it's nice of you to ask.
(3)
(0)
